ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck, U.S. Settle Vioxx Marketing Case

by Michael McCoy
November 28, 2011 | APPEARED IN VOLUME 89, ISSUE 48

Merck & Co. has agreed to pay $950 million to the U.S. and 43 states to resolve criminal charges and civil claims related to its promotion of the painkiller Vioxx. The settlement concludes a seven-year investigation of the firm, which acknowledges promoting Vioxx for rheumatoid arthritis for three years before it won approval for that application. Vioxx was withdrawn from the market in 2004 after it was found to increase the risk of heart attack and stroke.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment